Evidence map›Paper›PMID 40557324›Full record

ArticleFrontiers in cellular and infection microbiology2025

Evaluation of Beauvericin's activity and mode of action against all life stages of

Lynn Al Samra, Mohamad El Nahas, Ilham Mneimneh, Aia Sinno, Sima Tokajian, Kelven Rahy, Sergio Thoumi, Lazo Ali, Wael Yammine, Charbel Al Khoury

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lynn Al SamraDepartment of Natural Sciences, School of Arts and Sciences, Lebanese American University, Chouran, Beirut, Lebanon.
Mohamad El NahasDepartment of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
Ilham MneimnehDepartment of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
Aia SinnoDepartment of Natural Sciences, School of Arts and Sciences, Lebanese American University, Chouran, Beirut, Lebanon.
Sima TokajianDepartment of Natural Sciences, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon.
Kelven RahyGilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.
Sergio ThoumiDepartment of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
Lazo AliDepartment of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
Wael YammineDepartment of Plant Protection, Faculty of Agricultural & Veterinary Sciences, Lebanese University, Dekwaneh, Beirut, Lebanon.
Charbel Al KhouryDepartment of Natural Sciences, School of Arts and Sciences, Lebanese American University, Chouran, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leishmaniasis, particularly its cutaneous form caused by Objectives: This study investigates the potential of Beauvericin (BEA), a fungal secondary metabolite, as an alternative antileishmanial agent. Methods: We assessed the efficacy of BEA against different developmental stages of Results: BEA exhibited potent antileishmanial activity with equipotency across both promastigote and amastigote stages of Conclusions: BEA is a promising candidate for antileishmanial therapy, demonstrating superior efficacy, a broad mechanism of action, and a favorable resistance profile compared to ML. Further investigations in mammalian models are warranted to validate BEA's potential as a novel, cost-effective treatment for leishmaniasis.

Indexed as

Antiprotozoal AgentsDepsipeptidesLeishmaniasis, CutaneousLeishmania tropicaLife Cycle StagesAnimalsDisease Models, AnimalDrug ResistanceGene Expression ProfilingInhibitory Concentration 50Antiprotozoal AgentsbeauvericinDepsipeptidesBeauvericindrug resistanceGalleria mellonella modelLeishmaniasisLeishmania tropicaRNA-Seq

Identifiers

PMID40557324
PMCPMC12185981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.